Cargando…
A Catalog of 5’ Fusion Partners in ROS1-Positive NSCLC Circa 2020
ROS1 fusion–positive (ROS1+) NSCLC was discovered in 2007, the same year as the discovery of ALK-positive (ALK+) NSCLC but has trailed ALK+ NSCLC in terms of development. There seems to be a differential response to ROS1 inhibitors, which depend on fusion partners (CD74, SLC34A2, or SDC4); thus, kno...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474457/ https://www.ncbi.nlm.nih.gov/pubmed/34589944 http://dx.doi.org/10.1016/j.jtocrr.2020.100048 |